Heigener, D. and Gottfried, M. and Bennouna, J. and Bondarenko, I. and Douillard, J-Y. and Krzakowski, M. and Mellemgaard, A. and Novello, S. and Orlov, S. and Summers, Y.J. and von Pawel, J. and Hocke, J. and Kaiser, R. and Reck, M. (2016) Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study. Annals of Oncology, 27 (supp_6). 1276P-1276P. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
|
Text
Efficacy and safety of nintedanib.pdf Download (364kB) | Preview |
Abstract
Background: NIN is a triple angiokinase inhibitor approved in the EU in combination with DOC for the treatment of adenocarcinoma non-small cell lung cancer patients after first-line therapy (FLT). A continuous linear correlation between overall survival (OS) benefit with NIN and the predictive marker “time from start of FLT” (TSFLT) has been observed in adenocarcinoma patients. Methods: First, analyses were conducted of European adenocarcinoma patients, who comprise the majority of the population from the Phase III LUME-Lung 1 trial comparing NIN/DOC with placebo (PLA)/DOC (NCT00805194). Second, in order to further characterise time from FLT, analyses were conducted in adenocarcinoma populations defined by the dichotomisation at appropriate cut-points of TSFLT or progressive disease (PD) as best response to FLT. Analyses based on “time from end of FLT” (TEFLT) as described in other clinical trials were also performed.
| Item Type: | Article |
|---|---|
| Subjects: | Oncology |
| Divisions: | Departments > Department of Oncology and Medical Radiology |
| Depositing User: | Елена Шрамко |
| Date Deposited: | 20 Sep 2017 08:15 |
| Last Modified: | 20 Sep 2017 08:15 |
| URI: | http://repo.dma.dp.ua/id/eprint/1959 |
Actions (login required)
 |
View Item |
